Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1004 in Advanced NSCLC With EGFR ex20ins Mutation
NCT06015503Phase 2Active, not recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Jul 2023; status: active, not recruiting.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06015503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015503.